For patients without diabetes or clinical ASCVD with an estimated 10-year risk of CVD exceeding 10%, consideration of starting a GLP-1 RA carries a Class 2b, Level of Evidence C recommendation to reduce CV risk
[DOI] [PubMed] [Google Scholar] 17.Haws R., Brady S., Davis E., Fletty K., Yuan G., Gordon G., Stewart M., Yanovski J
Most telehealth GLP-1 programs are cash-pay
Physiological effect IGF-1 is also produced locally in all bodily tissues [6]
It also can reduce the levels of glutathione, which could affect the guts antioxidant capacity and thus increase the risk of the development of diseases, such as inflammatory bowel disease
The maximum recommended dose is 3,000 mg per day for over-the-counter use (up to 4,000 mg per day only with healthcare provider supervision)